Abstract
The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Current Bioactive Compounds
Title: Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Volume: 4 Issue: 2
Author(s): Vijaya L. Korlipara
Affiliation:
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Abstract: The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Export Options
About this article
Cite this article as:
Korlipara L. Vijaya, Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294235
DOI https://dx.doi.org/10.2174/157340708785294235 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Central Sensitisation Phenomena in Primary Headaches: Overview of a Preventive Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Human Exfoliated Deciduous Teeth Stem Cells: Features and Therapeutic Effects on Neurogenerative and Hepatobiliary-pancreatic Diseases
Current Stem Cell Research & Therapy Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry Relationship Between Polymerase Gamma (POLG) Polymorphisms and Antiretroviral Therapy-Induced Lipodystrophy in HIV-1 Infected Patients: A Case-Control Study
Current HIV Research Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Glucose Metabolism and Antidepressant Medication
Current Pharmaceutical Design ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design Glucose and LDL Lowering: The Need for Intensive Therapy
Current Vascular Pharmacology